MK-2206 2HCl

目录号:S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,在无细胞试验中IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。Phase 2。

规格 价格 库存 购买数量  
RMB 1789.01 现货
RMB 895.01 现货
RMB 1403.57 现货
RMB 3032.85 现货
RMB 4655.02 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献183篇:

客户使用该产品的21个实验数据:

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

  • (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

产品安全说明书

Akt抑制剂选择性比较

生物活性

产品描述 MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,在无细胞试验中IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。Phase 2。
特性 MK-2206是第一个进入临床研究阶段的Akt小分子变构抑制剂。
靶点
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
体外研究

MK-2206是变构抑制剂,由pleckstrin同源结构域激活。MK-2206抑制Akt的苏氨酸308位点和丝氨酸473位点的自身磷酸化作用。另外,MK-2206阻止Akt调节的下游信号分子(包括TSC2, PRAS40,及核糖体S6蛋白)的磷酸化作用。与抑制Ras 突变型细胞系(如NCI-H358, NCI-H23, NCI-H1299, 和Calu-6)相比,MK-2206 更有效地抑制Ras野生型细胞系(如A431, HCC827, 和NCI-H292)。MK-2206和细胞毒素药剂如erlotinib 和lapatinib联用作用于肺部NCI-H460肿瘤细胞或者卵巢A2780肿瘤细胞,MK-2206也显示出协同效应。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MUDDfZRwfG:6aXOgRZN{[Xl? MXWzJO69VQ>? NYPZVmx4PzJiaB?= NWTuRmlzTE2VTx?= MlLSTY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? NWDPcYh{OjB3N{GwOlk>
A431 MUjLbY5ie2ViQYPzZZk> MnzQOUDPxE1? NWPoeldjPSCq MkPJSG1UVw>? NUnm[ZR[W3WycILld5NmeyC2aHWgd4lodmGuaX7nJI9nKEGtdDDhcoQhTXKt NIrPNGMzODV5MUC2PS=>
HepG2 MmK2R5l1d3SxeHnjJGF{e2G7 NEXiTWoyOCEQvF2= NUjGO3ZTOjRiaB?= MX;EUXNQ MVzT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NIW2OlQzOTJyNUmyOS=>
Sk-Hep1 M3LzemN6fG:2b4jpZ{BCe3OjeR?= NXLweFQ4OTBizszN NFuxOHozPCCq NI\EWYpFVVOR M1HNc3NmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> Mki2NlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+) NX70b4huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfuW5I{KM7:TR?= MXq1JIQ> M4nhT2ROW09? MkjsTWM2OD1yLkG0JO69VQ>? NUDvSIZ5OjF{OEmyOlc>
K1 cells harbored PIK3CA (E542K+/+) MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe3PJBzOyEQvF2= MY[1JIQ> MmHrSG1UVw>? M{nNXGlEPTB;MD61NkDPxE1? NXfQ[lFROjF{OEmyOlc>
FTC133 cells harbored PTEN (allele deletion and R130+) MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnON{DPxE1? M3LBVlUh\A>? NW\0SVlTTE2VTx?= M37i[WlEPTB;MD6xPEDPxE1? M4nWTFIyOjh7Mk[3
C643 cells harbored HRAS (G13R+/−) NYLNOnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jLXFMh|ryP MoHROUBl MmPoSG1UVw>? NXftO|doUUN3ME2wMlI4KM7:TR?= MXOyNVI5QTJ4Nx?=
Hth7 cells harbored NRAS (Q61R+/−) NI[5WmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjwb4NuOyEQvF2= NHHSSpg2KGR? MV\EUXNQ NUTSTppbUUN3ME20MlUh|ryP NI\6boczOTJ6OUK2Oy=>
TPC1 cells harbored RET/PTC1 rearrangement NUDVUmNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vveVMh|ryP M4K4dVUh\A>? NUPsXJJXTE2VTx?= MYHJR|UxRTBwNUmg{txO Mlz4NlEzQDl{Nke=
Hth74 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;1bFMh|ryP NYTOR2VyPSCm MVrEUXNQ MV\JR|UxRTJwMUmg{txO NFXUTpczOTJ6OUK2Oy=>
KAT18 M3fMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOzJO69VQ>? NULiZ5l6PSCm NGP2cGxFVVOR M{Dp[mlEPTB;ND62NkDPxE1? MlHZNlEzQDl{Nke=
SW1736 NFXOXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHudHg4OTByIN88US=> NF\Obok2KGR? MWfEUXNQ NXPtTYZ2UUN3ME20O{42PiEQvF2= MVyyNVI5QTJ4Nx?=
WRO MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[zZVExODBizszN M4jiZ|Uh\A>? MoLqSG1UVw>? M1;VR2lEPTB-MUCwNEDPxE1? NEnGNpgzOTJ6OUK2Oy=>
TAD2 NV\mXlhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xNFAxKM7:TR?= MmHqOUBl NU\wbVRoTE2VTx?= NWPFNlhRUUN3ME6xNFAxKM7:TR?= NETjbIszOTJ6OUK2Oy=>
LN229 MUnBdI9xfG:|aYOgRZN{[Xl? MWOwMlUh|ryP NFHRflg3OCCq NFL6bYRFVVOR MWrBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? MXqyNlA2PzlzNB?=
T98G NUH4eIIySXCxcITvd4l{KEG|c3H5 NGLrTIgxNjVizszN NH6zbY83OCCq MnLCSG1UVw>? MXrBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? NVTYTJl6OjJyNUe5NVQ>
HC11 MYfGeY5kfGmxbjDBd5NigQ>? MoKyNVAh|ryP NEHiTJgzPCCq NV;oRYpYTE2VTx?= MYLJcohq[mm2czFOtk1k[XOnaX6gZY5lKEGGUmCgd5lvfGinc3nz M1rOflIzPDJ4NkKx
MOLT-4 MlTRR5l1d3SxeHnjJGF{e2G7 MWmxNEDPxE1? NGHYSIw1QCCq NYq1ZYJ1TE2VTx?= MYDJR|UxRTFwN,MAje69VQ>? NFjnXZAzOjZzNEK0Ny=>
CEM-R NXLWPIl7S3m2b4TvfIlkKEG|c3H5 NIG5WZAyOCEQvF2= NVLkfmFMPDhiaB?= NUjRVGl{TE2VTx?= NHW0WI9KSzVyPUOuN-KBkc7:TR?= MUSyNlYyPDJ2Mx?=
CEM-S NWDwdGRtS3m2b4TvfIlkKEG|c3H5 MWCxNEDPxE1? NX7IO|hTPDhiaB?= NIr4TIVFVVOR MULJR|UxRTVwMfMAje69VQ>? MYiyNlYyPDJ2Mx?=
MOLT-4 M1TGOmZ2dmO2aX;uJGF{e2G7 M{[yV|ExKM7:TR?= MXSyOEBp M2\o[GROW09? NUPhdGtPSmyxY3vzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?= MnjrNlI3OTR{NEO=
MOLT-4 NF7tUFJHfW6ldHnvckBCe3OjeR?= M3XIb|TjiIoQvF2= M1LzUVQhcA>? M1\2NmROW09? NHvxflNKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? M2e1SlIzPjF2MkSz
CEM-R MWnGeY5kfGmxbjDBd5NigQ>? M4T4OFTjiIoQvF2= Mn7KOEBp MmDmSG1UVw>? NXvCOW1JUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|RCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ MUeyNlYyPDJ2Mx?=
CEM-S MUfGeY5kfGmxbjDBd5NigQ>? M3\JSFTjiIoQvF2= MYq0JIg> NFX0TpRFVVOR M1vzWWlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO1RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? M{m0[FIzPjF2MkSz
HepG2 cell MmH6T4lv[XOnIFHzd4F6 MUmyNEDPxE1? MlnLNlQhcA>? M2jkNGROW09? M3mzOmRwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? MnrXNlM4QTd|MUm=
HepG2 cell MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfaN|Ah|ryP NUjqToI2OjRiaB?= MULEUXNQ Ml:4TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MXyyN|c6PzNzOR?=
HepG2 cell M17XXmFxd3C2b4Ppd{BCe3OjeR?= MUGyNEDPxE1? NV\qZ3d1OjRiaB?= MXvEUXNQ MofrTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MYmyN|c6PzNzOR?=
GEO NX[1TGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3LV2M2ODBibl2= NYnsfY0yPzJiaB?= NW\UfGZjTE2VTx?= NXvxdWxTUW6qaXLpeJMh[2WubDDndo94fGh? MXSyOFU5OTJ|MR?=
CNE-1 M4rDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rDOFExKM7:TR?= Mk\KPVYhcA>? MVzEUXNQ MmTzTWM2OD1{Lkm2JO69VQ>? MYGyOVM{Pjl{NR?=
CNE-2 NYj0TZp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKxNEDPxE1? MUW5OkBp M3rXbmROW09? MlXWTWM2OD12LkWzJO69VQ>? M1exb|I2OzN4OUK1
HONE-1 M1K4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe4RWEyOCEQvF2= MVq5OkBp NXqzNHJGTE2VTx?= MkjWTWM2OD1|LkO3JO69VQ>? M4jRfFI2OzN4OUK1
SUNE-1 M4nxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzxc3IyOCEQvF2= M4TUXVk3KGh? NFTzNJVFVVOR MknlTWM2OD1yLkWyJO69VQ>? Ml\FNlU{OzZ7MkW=
CNE-2 MmjCSpVv[3Srb36gRZN{[Xl? MVKxNEDPxE1? M2ToZVQ5KGh? Mny1SG1UVw>? M3zRXWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? MmrBNlU{OzZ7MkW=
HONE-1 NFjrTGRHfW6ldHnvckBCe3OjeR?= MVixNEDPxE1? NUHSNI42PDhiaB?= M4mzT2ROW09? NFq1[mJKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz NUnOeGE6OjV|M{[5NlU>
NEC8 NXSzcJVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:1c2lEPTB;MD6wPVY2OSEQvF2= M1W1XXNCVkeHUh?=
P12-ICHIKAWA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzKTWM2OD1yLkGxOlIh|ryP MnT5V2FPT0WU
MDA-MB-175-VII MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXXSoF5UUN3ME2wMlE{PzN6IN88US=> NXK0O2I{W0GQR1XS
AsPC-1 NYfUR3ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fnTWlEPTB;MD6yNlEzOiEQvF2= NHjqVnBUSU6JRWK=
T47D NITxUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXDTWM2OD1yLkK4NlUh|ryP MVvTRW5ITVJ?
HH M3\v[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTTTWM2OD1yLkOwNlg{KM7:TR?= MYjTRW5ITVJ?
MOLT-16 NGnUb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHpS29KSzVyPUCuN|A{OiEQvF2= NVr2b2JPW0GQR1XS
ES5 NVTiNm55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwM{S0OVUh|ryP MVvTRW5ITVJ?
RS4-11 NEjoXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwM{S2NUDPxE1? MUfTRW5ITVJ?
KARPAS-45 NVOy[lVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;1[ldKSzVyPUCuN|c{OjFizszN NWXpVWl3W0GQR1XS
NCI-H720 M{LaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XKSWlEPTB;MD6zO|Y4QSEQvF2= NI\BUGJUSU6JRWK=
H9 NGqwXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnkTWM2OD1yLkO4PFg{KM7:TR?= MVzTRW5ITVJ?
EFM-19 NIL5fo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHNTWM2OD1yLkS0NFEh|ryP M2iwTXNCVkeHUh?=
SBC-1 NHHNXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;BZoNKSzVyPUCuOFQxOzVizszN NF\5TWpUSU6JRWK=
A4-Fuk NEfhNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\qTWM2OD1yLkS2PFY5KM7:TR?= MlnuV2FPT0WU
NCI-H1563 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j4OWlEPTB;MD60PFE5QSEQvF2= MluyV2FPT0WU
HCC1419 NH;IV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvEe3VKSzVyPUCuOFg5QTJizszN MnP3V2FPT0WU
H-EMC-SS NIPiZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLuTWM2OD1yLkS5PVM6KM7:TR?= MYrTRW5ITVJ?
BHT-101 NGTV[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwNUK5OlEh|ryP NFLieZhUSU6JRWK=
IGROV-1 M4KzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH0TWM2OD1yLkW1NlQ6KM7:TR?= NV;aU3JNW0GQR1XS
HGC-27 MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;0TWM2OD1yLkW2O|g{KM7:TR?= MkHmV2FPT0WU
MDA-MB-361 M1G2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XRW2lEPTB;MD61O|c3OSEQvF2= MWLTRW5ITVJ?
KE-37 MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;jTHVKSzVyPUCuOVgzPiEQvF2= MmDGV2FPT0WU
HCC70 NVrTc24zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLZNXpvUUN3ME2wMlU6QDJ5IN88US=> MXjTRW5ITVJ?
LNCaP-Clone-FGC NXjQZWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nnOWlEPTB;MD62NVA1QCEQvF2= NFrJWJRUSU6JRWK=
HAL-01 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwNkKxN{DPxE1? NH;aXllUSU6JRWK=
HT MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwNkOyN|kh|ryP M13JWXNCVkeHUh?=
MDA-MB-415 NHLYSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[2XmlEPTB;MD62N|YzPiEQvF2= M2rFcnNCVkeHUh?=
NOS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37yUWlEPTB;MD62N|czOyEQvF2= M32zPHNCVkeHUh?=
DU-145 NWnDR5F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLCTWM2OD1yLk[0O|Q2KM7:TR?= NYDwbm1QW0GQR1XS
OCUB-M MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Tzd2lEPTB;MD63NFk3PiEQvF2= Mle5V2FPT0WU
VA-ES-BJ Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7DO3RvUUN3ME2wMlc{ODJ3IN88US=> NWjs[5psW0GQR1XS
J-RT3-T3-5 NH35UXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr3[VlKSzVyPUCuO|Q1ODNizszN M4eySHNCVkeHUh?=
MOLT-4 M{XXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uxcGlEPTB;MD64NFU5OiEQvF2= MV;TRW5ITVJ?
NB7 M4qwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X1UGlEPTB;MD64NlQyOSEQvF2= M1rRUHNCVkeHUh?=
L-363 NEH0fGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwOEO0OFIh|ryP NWnDN4ZYW0GQR1XS
NKM-1 MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XLW2lEPTB;MD64OlI2OyEQvF2= M4PCUXNCVkeHUh?=
HOP-92 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvzTWM2OD1yLki3NlI{KM7:TR?= MYrTRW5ITVJ?
OAW-42 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXkTWM2OD1yLki4O|Ih|ryP M1nqWXNCVkeHUh?=
HuO9 M372emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3hZ5RKSzVyPUCuPVI4PTFizszN MX7TRW5ITVJ?
MFE-280 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXKOJpKSzVyPUCuPVY1PjVizszN NF\RcXRUSU6JRWK=
EM-2 NWjSWXp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGwT3EyUUN3ME2wMlk4QTN7IN88US=> MUjTRW5ITVJ?
NCI-H520 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rNcGlEPTB;MD65PFU6OiEQvF2= MlHhV2FPT0WU
LB2241-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwOUm3N|Qh|ryP NHSyXGpUSU6JRWK=
SK-NEP-1 NYS0b2V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMUS0PFUh|ryP M{fGS3NCVkeHUh?=
LXF-289 NHfRNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\KWItoUUN3ME2xMlE4OTV4IN88US=> MnW5V2FPT0WU
EPLC-272H NWW1W45ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\hV2xsUUN3ME2xMlE4OjV4IN88US=> MnjLV2FPT0WU
COLO-684 MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor3TWM2OD1zLkKzO|I2KM7:TR?= MY\TRW5ITVJ?
ES1 NX\NXG5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7COmpKSzVyPUGuNlQxPjVizszN M3HuXHNCVkeHUh?=
DOHH-2 NHPTXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO4TWM2OD1zLkK4NlA{KM7:TR?= NXPuZYxXW0GQR1XS
CTB-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknoTWM2OD1zLkK4PVkh|ryP MmG5V2FPT0WU
G-401 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jPU2lEPTB;MT6yPVc6PSEQvF2= NIjWVlJUSU6JRWK=
LoVo MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO1N2N1UUN3ME2xMlMzPTN2IN88US=> MXXTRW5ITVJ?
Ramos-2G6-4C10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwM{O3NFEh|ryP MnryV2FPT0WU
MFM-223 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjITWM2OD1zLkO0OFYyKM7:TR?= M2DBcXNCVkeHUh?=
PA-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwM{WyOlUh|ryP MXzTRW5ITVJ?
697 NXm2WZZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfFZnN{UUN3ME2xMlM4PjF4IN88US=> MnK5V2FPT0WU
QIMR-WIL NHW0U5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvqPIlKSzVyPUGuOFkyOTZizszN MYDTRW5ITVJ?
HOS NIDKeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPRcGg{UUN3ME2xMlQ6PTV6IN88US=> NWDkRXFTW0GQR1XS
DMS-273 M4PwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:5TWM2OD1zLkWxPVU6KM7:TR?= NEfrc3lUSU6JRWK=
ME-180 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTEZ2p1UUN3ME2xMlU3QDlzIN88US=> M1XJeXNCVkeHUh?=
HCC2218 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[4Omp2UUN3ME2xMlY5OjJ3IN88US=> NIHxd29USU6JRWK=
CAL-54 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[3ZmlEPTB;MT63NVI1OiEQvF2= NFjLOJJUSU6JRWK=
OMC-1 M4DWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13QR2lEPTB;MT63OFY4PyEQvF2= M4HKWnNCVkeHUh?=
COR-L105 M3Tuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwN{m3N|ch|ryP MnzvV2FPT0WU
BV-173 M{Ttd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwOEGwO|Qh|ryP Mn:yV2FPT0WU
RKO M4jsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnZTWM2OD1zLki3NVAyKM7:TR?= M2eyd3NCVkeHUh?=
SNU-387 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rFVmlEPTB;MT64PFQxPiEQvF2= MXfTRW5ITVJ?
SW1088 NX;HSHB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7pTWM2OD1zLkm0OlA3KM7:TR?= MmnJV2FPT0WU
Hs-578-T NFzEfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\VTWM2OD1{LkGxOFM{KM7:TR?= MWfTRW5ITVJ?
OC-314 Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvyTWM2OD1{LkG1NFg3KM7:TR?= NEnFbZNUSU6JRWK=
RMG-I NV7jdFFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom4TWM2OD1{LkG2N|k5KM7:TR?= MXzTRW5ITVJ?
NCI-H1395 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwMUiwPVEh|ryP MX;TRW5ITVJ?
GAMG MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHHTWM2OD1{LkKzPFQ2KM7:TR?= MVjTRW5ITVJ?
LB1047-RCC NGrEdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwMkSzNVch|ryP NVuw[JZVW0GQR1XS
MN-60 NIPjdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[3WmlEPTB;Mj6yPVkzOyEQvF2= MkjtV2FPT0WU
OAW-28 NULBW2t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKyfGFKSzVyPUKuNlk6PTFizszN MVfTRW5ITVJ?
NCI-H2228 NXTqTVl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T1ZWlEPTB;Mj6zNVU2OiEQvF2= M1q1fHNCVkeHUh?=
ABC-1 NEn3XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHUR4FKSzVyPUKuN|MzPTNizszN MVfTRW5ITVJ?
LS-513 NFrpZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37TfWlEPTB;Mj6zN|Q5PCEQvF2= Ml7sV2FPT0WU
KS-1 NUHYU2FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq1RotKSzVyPUKuN|gyQTFizszN NVPZUmtbW0GQR1XS
NB69 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzFTWM2OD1{LkO4PVg{KM7:TR?= NX:1cIVEW0GQR1XS
VM-CUB-1 NXHjVm9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\hdYJKSzVyPUKuN|kxQDNizszN MXPTRW5ITVJ?
D-423MG NFXISWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL2b4RKSzVyPUKuOFExPDRizszN NVX6O456W0GQR1XS
EW-18 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e4b2lEPTB;Mj60NVk{QSEQvF2= MU\TRW5ITVJ?
YH-13 NHTGO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD2TWM2OD1{LkS2NVU{KM7:TR?= M1PLSHNCVkeHUh?=
T-24 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWzTIhXUUN3ME2yMlQ4QDhzIN88US=> MkC0V2FPT0WU
ES8 NIKyRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwNEmyPFch|ryP NVXyVZdoW0GQR1XS
ES3 NEXtPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO1PFhVUUN3ME2yMlQ6PzV7IN88US=> MVXTRW5ITVJ?
RXF393 NIDoXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nwRWlEPTB;Mj62NFQ5PyEQvF2= NGTBdpJUSU6JRWK=
RPMI-8226 M2q0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnWXVBvUUN3ME2yMlYzQTV|IN88US=> MoLxV2FPT0WU
AGS NGrBcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJwN{KxN|ch|ryP MUTTRW5ITVJ?
HCC1395 NFHobZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwN{WxPFch|ryP NYe3U4s3W0GQR1XS
MV-4-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX3TWM2OD1{Lke1NlY3KM7:TR?= MlPnV2FPT0WU
A204 NUP3bWdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwOEO4O|Ih|ryP NHjzeJJUSU6JRWK=
MCF7 M{HQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHrTWM2OD1{Lki2NVE4KM7:TR?= MVPTRW5ITVJ?
SNU-423 MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlraTWM2OD1{Lki5NlQzKM7:TR?= NGfiXplUSU6JRWK=
NCI-H1048 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT1fWZsUUN3ME2yMlk3QDZ3IN88US=> M2rUeHNCVkeHUh?=
GR-ST M1TxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNwMES2NVEh|ryP NHHFem1USU6JRWK=
EoL-1- NH3OcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwMEewOVgh|ryP MlnpV2FPT0WU
HuH-7 M{HaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNwMEm0OlQh|ryP MXfTRW5ITVJ?
OS-RC-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj5XGZ3UUN3ME2zMlEyOTlizszN M2jtTXNCVkeHUh?=
EW-3 NVO5XlB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LaUmlEPTB;Mz6xPVUzQSEQvF2= MkHoV2FPT0WU
NCI-H747 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNwMkC2PVQh|ryP NIrCZYNUSU6JRWK=
EW-16 NWHwXJJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe1d5Z5UUN3ME2zMlIyQDd7IN88US=> MYLTRW5ITVJ?
DOK M1nBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;xWnJKSzVyPUOuNlI5PTlizszN MkjYV2FPT0WU
HCC2157 NXu2[3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwM{ixO|kh|ryP M2jVdHNCVkeHUh?=
OVCAR-3 NF;R[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITRV3RKSzVyPUOuOFA4QDZizszN Mm\lV2FPT0WU
NCI-H1623 M{i1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfTZVRKSzVyPUOuOFEzOjRizszN NUD0RVJMW0GQR1XS
H4 NIHDfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfGN|NTUUN3ME2zMlQ2PjJ4IN88US=> NFPhcHFUSU6JRWK=
SW1710 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNwNE[2O|gh|ryP M1\LVnNCVkeHUh?=
RT-112 NHnrOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7xTWM2OD1|LkWyN|g5KM7:TR?= MWrTRW5ITVJ?
DMS-114 NV7FfJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTpTWM2OD1|Lk[yNlc5KM7:TR?= NXHDUYprW0GQR1XS
AN3-CA MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTNwNkK0OVYh|ryP MYXTRW5ITVJ?
KNS-62 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fnSGlEPTB;Mz62N|M{QCEQvF2= MnrmV2FPT0WU
SJRH30 NEXqTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOwPIRuUUN3ME2zMlY6OTJ{IN88US=> Mor4V2FPT0WU
G-402 M4[wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOxZoRKSzVyPUOuO|A4OTFizszN MlPwV2FPT0WU
MHH-PREB-1 NULV[ZZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\xTGptUUN3ME2zMlczODN6IN88US=> MlzKV2FPT0WU
P30-OHK Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwOEC5O|Yh|ryP NXHZ[XZzW0GQR1XS
RVH-421 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTNwOEG3PFgh|ryP NV7mNGNnW0GQR1XS
LU-134-A M4[2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7KTWM2OD1|Lki4OFI5KM7:TR?= MmPNV2FPT0WU
ECC10 NV3OdmtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nhS2lEPTB;Mz65N|YzOiEQvF2= NVzuVox6W0GQR1XS
TGW NVLE[FUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH2WFdYUUN3ME20MlAzOzB3IN88US=> NHvRfVNUSU6JRWK=
MLMA M3jtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRwMEK5OlYh|ryP NFy0e5BUSU6JRWK=
SCC-25 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7BU2xKSzVyPUSuNFY2PjZizszN NVzzRo1IW0GQR1XS
TYK-nu NXPVNmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjzTWM2OD12LkC5OVM1KM7:TR?= NE\3[JlUSU6JRWK=
LAMA-84 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRwMUSxPVEh|ryP M3LOe3NCVkeHUh?=
Calu-3 M12yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTRwMkS0NVYh|ryP NXzqVpZlW0GQR1XS
NCI-H460 NGTGTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHmWXVOUUN3ME20MlI3PDR|IN88US=> MV\TRW5ITVJ?
EGI-1 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHD[I1KSzVyPUSuN|c4PzhizszN NWnJW3hRW0GQR1XS
NCI-H292 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXjTWM2OD12LkO4NVQ3KM7:TR?= Mmn5V2FPT0WU
HCE-T MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnlfZlKSzVyPUSuOFE2PzlizszN M1y1fHNCVkeHUh?=
EW-11 NGLYempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W0NmlEPTB;ND60NVg{QCEQvF2= M2fpe3NCVkeHUh?=
ATN-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH30dHJKSzVyPUSuOFQ{ODRizszN MXjTRW5ITVJ?
NB5 NHfy[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\1Z3A2UUN3ME20MlU{Pjl5IN88US=> MofIV2FPT0WU
KLE M2fjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e0[WlEPTB;ND63NFE6QCEQvF2= MVPTRW5ITVJ?
CAL-39 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwN{KxOFYh|ryP NYT6dFRJW0GQR1XS
TI-73 NHr2[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi4N2VKSzVyPUSuPFA3ODlizszN M{KzSXNCVkeHUh?=
HO-1-N-1 NHvuW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjj[ItWUUN3ME20Mlk1OiEQvF2= MoPwV2FPT0WU
786-0 NYPnXnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ewNWlEPTB;ND65OFY4OyEQvF2= NE[1WWRUSU6JRWK=
SK-N-DZ MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFryemVKSzVyPUSuPVYyPDJizszN MXrTRW5ITVJ?
NCI-H446 M4jSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;WW|VKSzVyPUWuNlAxODlizszN MnmzV2FPT0WU
ETK-1 NF7nZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XwXWlEPTB;NT6yNVE3PSEQvF2= NG\neoFUSU6JRWK=
BT-20 M3\OUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjqVmFKSzVyPUWuNlE{PTNizszN MmHNV2FPT0WU
MEL-HO NI\6[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfkVGlKSzVyPUWuN|c{OzZizszN NGLudpFUSU6JRWK=
CAL-27 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHW[GlJUUN3ME21MlQ3OzN7IN88US=> MlnqV2FPT0WU
SW872 M3PON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXCUHdSUUN3ME21MlU6PDJ6IN88US=> NFfwNoZUSU6JRWK=
RPMI-2650 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDTTWM2OD13Lk[2NVk6KM7:TR?= NEHGc3NUSU6JRWK=
PFSK-1 NH\zc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInEUnhKSzVyPUWuO|I4OzJizszN NVXsXHF7W0GQR1XS
SF295 NEjuWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn4N5RKSzVyPUWuPFA3OzNizszN MoDtV2FPT0WU
Becker MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm5b3hDUUN3ME21Mlg3PDd{IN88US=> M4r1XHNCVkeHUh?=
Saos-2 M4qzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrNTWM2OD13Lki2OVMh|ryP MUfTRW5ITVJ?
SK-OV-3 M1q5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfMTWM2OD13Lkm5PFE3KM7:TR?= NH7PfJhUSU6JRWK=
VMRC-RCZ NEPqSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfCdm1KSzVyPU[uNFg4PzNizszN NH7x[phUSU6JRWK=
EW-22 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nObGlEPTB;Nj6xPVY1QSEQvF2= NYfmVpFRW0GQR1XS
BT-474 NEPBUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HGSGlEPTB;Nj6yN|Mh|ryP NVjiSFdiW0GQR1XS
BFTC-909 NIC2e5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHXfoFnUUN3ME22MlMxOzR3IN88US=> NWfZR4NoW0GQR1XS
NB12 NV;rO5RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LZZmlEPTB;Nj6zPVA4OSEQvF2= MVfTRW5ITVJ?
D-263MG MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELz[VlKSzVyPU[uOFUyPjlizszN Mn;hV2FPT0WU
SNB75 NEPXO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwNkCxOFMh|ryP NIjUUGRUSU6JRWK=
A704 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\KTWM2OD14Lk[zNFYh|ryP MlnHV2FPT0WU
NCI-H1693 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fxXmlEPTB;Nj62N|YxPCEQvF2= NVf4NYF3W0GQR1XS
LN-405 NV\ibYV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TN[GlEPTB;Nj63PVY4OiEQvF2= MUPTRW5ITVJ?
CHL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX1VZA3UUN3ME22MlgxODd7IN88US=> M2C5RnNCVkeHUh?=
A498 NFPRd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS2foIzUUN3ME22MlgyQTZzIN88US=> NFGz[VJUSU6JRWK=
TE-12 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HXSWlEPTB;Nj64N|gyPyEQvF2= MmWxV2FPT0WU
TE-6 NW\3cWQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[5VndKSzVyPU[uPVMxOzhizszN M2TvXnNCVkeHUh?=
AU565 NEnUW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDNTWM2OD14Lkm2PVU4KM7:TR?= MnfrV2FPT0WU
RD NEDNS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m2SmlEPTB;Nj65PFI5PCEQvF2= M1fCcXNCVkeHUh?=
SW1463 M1njTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPNZpBKSzVyPUeuNVEyPjhizszN M3SwTHNCVkeHUh?=
LU-99A NFHvWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLXTIpKSzVyPUeuNVQ{OjJizszN MUTTRW5ITVJ?
NCI-H28 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LEXWlEPTB;Nz6yPVI1KM7:TR?= NFjHXnRUSU6JRWK=
MC-IXC NYO1PYJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTdwNEi1O|Yh|ryP MYHTRW5ITVJ?
GP5d NIiwVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vYWmlEPTB;Nz60PFc3PCEQvF2= MlzsV2FPT0WU
GB-1 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLsTWM2OD15LkW0PFA1KM7:TR?= NYLpXlk1W0GQR1XS
CAL-33 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PiU2lEPTB;Nz62OlI{OyEQvF2= M1K0XnNCVkeHUh?=
MSTO-211H M2f3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTdwNkezN|Yh|ryP M4j1W3NCVkeHUh?=
TE-5 NHmyN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTdwN{mzN|Qh|ryP NHPOfJZUSU6JRWK=
D-566MG MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\jbVlkUUN3ME24MlA1PDJ7IN88US=> Mnq5V2FPT0WU
JVM-3 NIr4NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfvc3ZKSzVyPUiuNVUzPjhizszN NE[xSWxUSU6JRWK=
T98G MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KwTmlEPTB;OD6xPFA3PyEQvF2= NVXXS3V4W0GQR1XS
HCC1954 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[we2lEPTB;OD60OVExPCEQvF2= M1HEcnNCVkeHUh?=
SF126 NE\ubpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG0TWM2OD16LkS1PVM3KM7:TR?= NWrwN5poW0GQR1XS
LB996-RCC NV7FRYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\qZWlEPTB;OD61N|I2PyEQvF2= NH;YXXhUSU6JRWK=
SKG-IIIa MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRThwNkOwOlkh|ryP NGfJZ5pUSU6JRWK=
NCI-SNU-1 Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRThwNkS2OFMh|ryP Mnq5V2FPT0WU
LB771-HNC NEL4NWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW0[|JHUUN3ME24MlY1Pjl4IN88US=> MlHxV2FPT0WU
SCC-4 NI[xdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nPcWlEPTB;OD62PFIyQSEQvF2= NGDETohUSU6JRWK=
CAMA-1 M4exPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MleyTWM2OD16Lke3NVQ3KM7:TR?= MWHTRW5ITVJ?
D-502MG Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWwbXFKSzVyPUiuO|g3OjlizszN M1exNXNCVkeHUh?=
ESS-1 NIfmVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDlTWM2OD16Lki4O|A1KM7:TR?= NEDEU5dUSU6JRWK=
HEC-1 M3nVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7JNYlKSzVyPUiuPFk5PjZizszN NIHTbIpUSU6JRWK=
NB10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTlwMEKyNlQh|ryP MYHTRW5ITVJ?
8505C M{L3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\3TXdKSzVyPUmuNFQzOzJizszN NGK3OVNUSU6JRWK=
EFO-27 NGLNVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTlwMU[0NVIh|ryP NGjPZYdUSU6JRWK=
HN NHLWZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\4b5lKSzVyPUmuNVY3OjhizszN M{eyWnNCVkeHUh?=
DSH1 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLETWM2OD17LkKwPFch|ryP Mo\RV2FPT0WU
NBsusSR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;1TWM2OD17LkK3OFAzKM7:TR?= M17uSXNCVkeHUh?=
LS-123 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX61UFNHUUN3ME25MlMyPzZzIN88US=> NF;3PGJUSU6JRWK=
SHP-77 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTlwM{m5N|Uh|ryP M3HSUXNCVkeHUh?=
ACN NHjWU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\BXGlEPTB;OT61N|I4PyEQvF2= NETqV|RUSU6JRWK=
U251 NGX4NXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTlwNkW1OFQh|ryP MmrXV2FPT0WU
A431 NGT5SlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX3OFlKSzVyPUmuPFAzOzhizszN NGr0bGFUSU6JRWK=
5637 NEPBSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTKTWM2OD17Lki0PVg1KM7:TR?= M1;LTnNCVkeHUh?=
MDA-MB-157 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;CbmlEPTB;OT65Nlg4QCEQvF2= NImzeYlUSU6JRWK=
A101D NIW3[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nu[WlEPTB;OT65PVk4PCEQvF2= Mo\2V2FPT0WU
YKG-1 NXvCbZJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPlcVRKSzVyPUGwMlIxODZizszN M4G1b3NCVkeHUh?=
LAN-6 NELJNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH4eXRQUUN3ME2xNE4zOTZ2IN88US=> M4DQbnNCVkeHUh?=
OVCAR-5 NFHIWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nUTWlEPTB;MUCuNlQ{OyEQvF2= MUnTRW5ITVJ?
A549 NEPNWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFyLkO5O|Mh|ryP MYPTRW5ITVJ?
no-11 NW\ufFVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HoVWlEPTB;MUCuOFM2OyEQvF2= NWHDRmFwW0GQR1XS
SF539 M17JNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqwTWM2OD1zMD65NFQyKM7:TR?= MoHDV2FPT0WU
A388 NIPsfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHGfoRKSzVyPUGxMlM5QTdizszN M4m0WHNCVkeHUh?=
DEL M1zOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFzLkSyOEDPxE1? MlmxV2FPT0WU
SW954 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLGTFhKSzVyPUGxMlQ3PjhizszN NUHvNJZoW0GQR1XS
TK10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\yTWM2OD1zMT61NlcyKM7:TR?= MUfTRW5ITVJ?
SW756 MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXafpJDUUN3ME2xNU42Ojl2IN88US=> MV7TRW5ITVJ?
PC-3 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXlTWM2OD1zMT61O|Y1KM7:TR?= M1HFO3NCVkeHUh?=
ONS-76 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofWTWM2OD1zMT62N|Yh|ryP MoX6V2FPT0WU
A427 NETU[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn4UHVKSzVyPUGxMlcxQTNizszN NUD2d3JpW0GQR1XS
MEG-01 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITtR3VKSzVyPUGxMlc2ODlizszN NF\mOoJUSU6JRWK=
BB30-HNC NYjlWnZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrhTG1KSzVyPUGxMlc6QDJizszN M3;scXNCVkeHUh?=
NCI-H1299 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXneJNKSzVyPUGxMlgxQTNizszN NGj0VZdUSU6JRWK=
GCT MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\vfllKSzVyPUGxMlgzOjhizszN M4XxcHNCVkeHUh?=
D-247MG NFvFemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrXbFRKSzVyPUGxMlk3PjNizszN MYnTRW5ITVJ?
CFPAC-1 NVzz[VRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\LNoVvUUN3ME2xNU46Pzh{IN88US=> M4DpVXNCVkeHUh?=
EKVX M4r3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLxXYpVUUN3ME2xNk4xOzF|IN88US=> NFfSVJFUSU6JRWK=
CAL-51 M3juN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7JRYhtUUN3ME2xNk4xPzF4IN88US=> NF:wT2NUSU6JRWK=
BB49-HNC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon1TWM2OD1zMj6xNVc4KM7:TR?= NHGwRlRUSU6JRWK=
RPMI-7951 M1LHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;DS4trUUN3ME2xNk4yQDV2IN88US=> NVy3O3JiW0GQR1XS
RH-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHjSo1KUUN3ME2xNk4zOTh2IN88US=> M3zKOnNCVkeHUh?=
BCPAP NVnlU|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[xTWM2OD1zMj60O|Q6KM7:TR?= MUTTRW5ITVJ?
GCIY NWj5Zmt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7zTWM2OD1zMj61NlA6KM7:TR?= M3;4TXNCVkeHUh?=
KNS-81-FD MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[3TWM2OD1zMj61PFY6KM7:TR?= NWmxTGFMW0GQR1XS
KYSE-140 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF{Lki1PVUh|ryP MmXtV2FPT0WU
Ca-Ski MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTlTWM2OD1zMj65NFQyKM7:TR?= M{P3dHNCVkeHUh?=
TGBC1TKB NWjjTnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXCOI5KSzVyPUGyMlkyOTVizszN M{fpRXNCVkeHUh?=
HCC1187 NV\icolbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ESmlEPTB;MUOuNVkyOiEQvF2= NH;DSndUSU6JRWK=
SJSA-1 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|LkKzNlch|ryP M{mzcHNCVkeHUh?=
CTV-1 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7CTWM2OD1zMz6zOFUh|ryP NF33S|VUSU6JRWK=
WM-115 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n3U2lEPTB;MUOuOlQ5OyEQvF2= NXHDeWQ3W0GQR1XS
CHP-212 M3vZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rnTmlEPTB;MUOuPVc{QSEQvF2= NVe0UnppW0GQR1XS
SCC-15 NV7z[YFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTDTWM2OD1zMz65O|c2KM7:TR?= M2DXSHNCVkeHUh?=
BPH-1 NVPIeXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XmWWlEPTB;MUSuNVY3PCEQvF2= MWnTRW5ITVJ?
SW780 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HTUGlEPTB;MUSuOVAzPSEQvF2= M4LIVXNCVkeHUh?=
NCI-H2291 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HENGlEPTB;MUSuOVg4QCEQvF2= MWPTRW5ITVJ?
JEG-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF2Lk[zNlYh|ryP MmnKV2FPT0WU
CAL-120 NIDDWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rRcWlEPTB;MUSuO|AzPyEQvF2= MUDTRW5ITVJ?
NCI-H23 NF7pTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\6SHdwUUN3ME2xOE44QTl5IN88US=> M2nReXNCVkeHUh?=
MS-1 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrHUolKSzVyPUG0Mlk3OTFizszN MXPTRW5ITVJ?
PC-14 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF2Lkm2OVQh|ryP NGO3SGpUSU6JRWK=
D-283MED NVfNXJMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzaflh2UUN3ME2xOU4xOTFzIN88US=> MmnlV2FPT0WU
OE19 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXRTWM2OD1zNT6xOVQyKM7:TR?= NHvyZWpUSU6JRWK=
CAS-1 M2TBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF3LkSxPFQh|ryP NXv6UpNxW0GQR1XS
NCI-H727 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrtVnJKSzVyPUG1MlQzOjFizszN MVXTRW5ITVJ?
SiHa MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF3Lke1PVQh|ryP NV23RmczW0GQR1XS
BFTC-905 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\yXml2UUN3ME2xOU44Pjl2IN88US=> NHPO[FFUSU6JRWK=
MDA-MB-453 NWC4[nBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLJTWM2OD1zNj6xOlQzKM7:TR?= NH7ZVlRUSU6JRWK=
HuP-T3 NWS5OYV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHNbVFSUUN3ME2xOk43Ozd|IN88US=> NFfIPXpUSU6JRWK=
SK-LU-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF4Lk[5OVYh|ryP NIHveYJUSU6JRWK=
Detroit562 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF4LkezNVgh|ryP MnvHV2FPT0WU
HCC1569 NIO3To9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF4LkizN|ch|ryP M3;aWnNCVkeHUh?=
SK-MES-1 M1ThPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF4Lki0NVkh|ryP NV:1e2hVW0GQR1XS
BB65-RCC NEnsV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HQdGlEPTB;MUeuNFQ4QSEQvF2= MVPTRW5ITVJ?
LOXIMVI M4jCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTYZol5UUN3ME2xO{4xPzB5IN88US=> MVXTRW5ITVJ?
SW1783 NVSyZWp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\NTGlEPTB;MUeuNVI5KM7:TR?= M4PQTnNCVkeHUh?=
NH-12 M3LYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHUSYVKSzVyPUG3MlM{ODNizszN MYDTRW5ITVJ?
UACC-257 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\PTWM2OD1zNz61OVEzKM7:TR?= NEH4SIZUSU6JRWK=
KOSC-2 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPnTWM2OD1zNz62O|U4KM7:TR?= M2HCcnNCVkeHUh?=
KG-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILZdZhKSzVyPUG3MlY6OzdizszN NUXFRm1zW0GQR1XS
M059J MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTmZo9mUUN3ME2xO{44ODNizszN MXTTRW5ITVJ?
MHH-NB-11 NXXZUIJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrRW4hKSzVyPUG3Mlk3PzNizszN MlO2V2FPT0WU
EW-1 NV7xRpZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjNU4NKUUN3ME2xPE4yOzh{IN88US=> M{TINXNCVkeHUh?=
CAL-85-1 M{PEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLSTWM2OD1zOD6yN|U4KM7:TR?= MoKyV2FPT0WU
639-V MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS2U4lVUUN3ME2xPE4{OzV2IN88US=> M{fqPHNCVkeHUh?=
C32 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF6LkS3Nlch|ryP M1LYU3NCVkeHUh?=
KM-H2 M1f4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF6LkWyN|Ih|ryP NIH2XpVUSU6JRWK=
A253 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr3e4VtUUN3ME2xPE44Ojh4IN88US=> MUPTRW5ITVJ?
NCI-N87 NHfBfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fEO2lEPTB;MUiuPVAxQCEQvF2= MXPTRW5ITVJ?
8-MG-BA MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnvb|V{UUN3ME2xPU4xPjR4IN88US=> MYXTRW5ITVJ?
GI-ME-N MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF7LkG1OFYh|ryP MX;TRW5ITVJ?
8305C NVPIOYs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH63TppKSzVyPUG5MlIzQDZizszN NFf4SXdUSU6JRWK=
TE-8 NHnFT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zrO2lEPTB;MUmuN|AzPCEQvF2= NWe5dYUzW0GQR1XS
KYSE-270 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DofmlEPTB;MkCuNFIyPyEQvF2= MlfqV2FPT0WU
HL-60 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjNe244UUN3ME2yNE4xQTRzIN88US=> M2ntRXNCVkeHUh?=
Mo-T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLQTWM2OD1{MD6xOlY2KM7:TR?= MYfTRW5ITVJ?
NCI-H1355 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\iTWM2OD1{MD6zN|c1KM7:TR?= M2i1THNCVkeHUh?=
HT-1080 M{HETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nkTWlEPTB;MkCuOVQ6PyEQvF2= Mo\vV2FPT0WU
MIA-PaCa-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu1SlhqUUN3ME2yNE43QDh|IN88US=> MXvTRW5ITVJ?
NCI-H441 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\LTWM2OD1{MD63N|c6KM7:TR?= NUTPd3pRW0GQR1XS
LCLC-97TM1 NIPpSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO4TWM2OD1{MD64NVM1KM7:TR?= M{e5SHNCVkeHUh?=
HT-3 NV70WHZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fzXmlEPTB;MkGuOVY{OSEQvF2= M2X0[XNCVkeHUh?=
22RV1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37wdGlEPTB;MkGuOVY5PSEQvF2= MorQV2FPT0WU
LK-2 M13COmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi1TWM2OD1{MT61PVU{KM7:TR?= NX\ydlM{W0GQR1XS
CW-2 NHvwbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e4XGlEPTB;MkGuOlA3QSEQvF2= NUK4NXRQW0GQR1XS
KYSE-510 M4DLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13MdGlEPTB;MkGuOlA6PSEQvF2= NYDTNGNTW0GQR1XS
CGTH-W-1 Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLCU4dKSzVyPUKxMlcyPjZizszN MmDMV2FPT0WU
NCI-H661 M1i3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ{LkCzOEDPxE1? Ml22V2FPT0WU
KU-19-19 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvuUo9zUUN3ME2yNk4yPjl5IN88US=> NGqwO21USU6JRWK=
NCI-H2122 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7wUGpKSzVyPUKyMlI1OzJizszN MYLTRW5ITVJ?
NCI-H526 NF7SVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJ{LkO4PVUh|ryP NEDXZpNUSU6JRWK=
NCI-H1650 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;kTWM2OD1{Mj63OlQh|ryP MlrGV2FPT0WU
AM-38 NH3X[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TBV2lEPTB;MkKuPFY5QSEQvF2= NFzHRXRUSU6JRWK=
NCI-H2405 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DORmlEPTB;MkOuNlU{OyEQvF2= M4\CV3NCVkeHUh?=
M14 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ|LkSwPFgh|ryP M3\se3NCVkeHUh?=
ES4 NXnhWFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLXcZJKSzVyPUKzMlQzOzJizszN MV7TRW5ITVJ?
DJM-1 M{HMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuzelNKSzVyPUKzMlUzOzRizszN MYnTRW5ITVJ?
S-117 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlKwTWM2OD1{Mz63OlUyKM7:TR?= NIHtUYJUSU6JRWK=
MZ2-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7OXYxKSzVyPUKzMlc4PTlizszN NEfkWWlUSU6JRWK=
SK-MEL-2 M1nXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ|LkixN|Mh|ryP Mn3sV2FPT0WU
HCC1806 NVnnb3lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33zSWlEPTB;MkOuPFcxQSEQvF2= Mo\OV2FPT0WU
NMC-G1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjsWZVKSzVyPUK0MlIzOjZizszN NEfJeGNUSU6JRWK=
DK-MG Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nj[WlEPTB;MkSuNlk1KM7:TR?= NHPieopUSU6JRWK=
SK-N-FI NV\3U3ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ2LkOzNFIh|ryP MWnTRW5ITVJ?
KINGS-1 NGrFXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDuNXdKSzVyPUK0MlQ5PzRizszN MW\TRW5ITVJ?
HCC2998 NIj5PZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrrdpVKSzVyPUK0MlQ5QDVizszN NFK3cmVUSU6JRWK=
ALL-PO NH3YVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrWOYRRUUN3ME2yOE43OTlizszN NXnMXnVOW0GQR1XS
MPP-89 NXPKR29[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjlS|ZKSzVyPUK1MlA1PThizszN MUXTRW5ITVJ?
NCI-H2342 NVLvSVdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3KXJV1UUN3ME2yOU4yQTV|IN88US=> Mm\HV2FPT0WU
TE-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TiUWlEPTB;MkWuN|U3OyEQvF2= MlroV2FPT0WU
RH-18 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ3LkW5NVgh|ryP NIHsOoZUSU6JRWK=
HT-1376 M4nPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jGZWlEPTB;MkWuOlQ3PSEQvF2= M2TnR3NCVkeHUh?=
U-2-OS NEf5bHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHlTWM2OD1{NT62PFg5KM7:TR?= NGC3ZZRUSU6JRWK=
BT-549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[wcoJKSzVyPUK1MlkxOTFizszN NV3YXod[W0GQR1XS
NCI-H1755 NF7LV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLPWIVKSzVyPUK1Mlk6PDVizszN NVzZZllvW0GQR1XS
EW-13 NEPuSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HQb2lEPTB;Mk[uNFI4PCEQvF2= NULOWGp3W0GQR1XS
NB13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jHXWlEPTB;Mk[uNFk1QSEQvF2= NHnBXotUSU6JRWK=
NUGC-3 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ4LkKxNFMh|ryP NH20UHRUSU6JRWK=
GMS-10 NGnzUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXp[HVxUUN3ME2yOk4zOzV|IN88US=> MYnTRW5ITVJ?
CHP-134 NVPYWYJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ4LkO4Olch|ryP NHTIfXhUSU6JRWK=
SW962 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjBTWM2OD1{Nj61NFIyKM7:TR?= MnjvV2FPT0WU
SNU-449 NFv3XGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJ5LkC4NFMh|ryP M1LLbHNCVkeHUh?=
HuP-T4 NEHGXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rp[2lEPTB;MkeuNFg4QSEQvF2= NX\6VHdTW0GQR1XS
SW948 NXjKWmNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz3N5BKSzVyPUK3MlE{PDRizszN M1vLPXNCVkeHUh?=
NCI-H226 NILLRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ5LkS1O|gh|ryP NHHJTYRUSU6JRWK=
SK-PN-DW NFXs[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D1RWlEPTB;MkeuOlAyOiEQvF2= MkDaV2FPT0WU
GI-1 M{jxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\iTZJPUUN3ME2yO{44OjFizszN NFrtWI1USU6JRWK=
CAL-12T M{nzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HkemlEPTB;MkiuNVEyOiEQvF2= MoHWV2FPT0WU
YAPC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjKTWM2OD1{OD6yOVY1KM7:TR?= NXHoTnFNW0GQR1XS
SNU-C2B NGL4NoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnKTWM2OD1{OD6yPVY1KM7:TR?= M{Di[XNCVkeHUh?=
RCC10RGB NHv0OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzKUoM4UUN3ME2yPE42PDF5IN88US=> MXzTRW5ITVJ?
ES7 Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJ7LkG0OlUh|ryP M3\TdHNCVkeHUh?=
PANC-03-27 NVzzT3NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfhV|lvUUN3ME2yPU41PDRizszN MUPTRW5ITVJ?
ES6 M2i1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJ7LkixOVch|ryP M2TmVHNCVkeHUh?=
HT-1197 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17NS2lEPTB;M{CuNFU6QCEQvF2= MWfTRW5ITVJ?
ZR-75-30 NE\I[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nLd2lEPTB;M{CuNlM5OyEQvF2= M3u1T3NCVkeHUh?=
DB MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXHZ21KSzVyPUOwMlQ6PDJizszN M1e3[XNCVkeHUh?=
OCI-AML2 M2eyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13FPGlEPTB;M{GuNFY6KM7:TR?= MUPTRW5ITVJ?
NCI-H2170 NGLyWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3q[nNKSzVyPUOxMlg2OTZizszN M1zIO3NCVkeHUh?=
IST-MES1 NXT4ToJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHiSFNUUUN3ME2zNk4zQDl5IN88US=> NYXMVZNFW0GQR1XS
769-P M3vRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHEW2NKSzVyPUOyMlM3PDFizszN NVjFWZBxW0GQR1XS
COR-L23 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfzTWM2OD1|Mj65NFc{KM7:TR?= M4P6SHNCVkeHUh?=
SW626 M{LsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHLNGJwUUN3ME2zN{4yPzd4IN88US=> MVTTRW5ITVJ?
LU-139 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTN|Lk[2NFUh|ryP MnfrV2FPT0WU
HT-144 MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPOXo5sUUN3ME2zN{45PjNizszN MUDTRW5ITVJ?
CaR-1 NH7uVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7sT2ZDUUN3ME2zN{46QDJ{IN88US=> NELKRXNUSU6JRWK=
OE33 NFfzR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTDTWM2OD1|ND6yPFU2KM7:TR?= MWjTRW5ITVJ?
COLO-800 NIHybnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojBTWM2OD1|ND6zOlQ4KM7:TR?= MVrTRW5ITVJ?
NB14 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3uNZZKSzVyPUO0MlQ3QDRizszN M2LKb3NCVkeHUh?=
KURAMOCHI NYDIVmJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7YbW5KSzVyPUO2MlEyQThizszN NVTRWGNMW0GQR1XS
SW48 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN4LkK0O|Qh|ryP MkX1V2FPT0WU
Daoy MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn0PINKSzVyPUO2MlY2OzhizszN NWjmWYVyW0GQR1XS
TGBC24TKB NInSSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hpc2lEPTB;M{[uOlch|ryP M{nDXnNCVkeHUh?=
DU-4475 M3\3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;vZ2lEPTB;M{[uPVA{OyEQvF2= Mk[wV2FPT0WU
SW1417 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS0e|RKSzVyPUO4MlA2PTJizszN MYPTRW5ITVJ?
EFO-21 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTU[21GUUN3ME2zPE46OzR7IN88US=> NF20ZlNUSU6JRWK=
MG-63 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTN7LkO0NlQh|ryP M3fxNXNCVkeHUh?=
LC-2-ad NE\UT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrYT2NiUUN3ME2zPU42PTF{IN88US=> NIDreFdUSU6JRWK=
NOMO-1 M3fkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;aPIhKSzVyPUO5MlgzPzRizszN MW\TRW5ITVJ?
COLO-741 NV;WRZR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n0eGlEPTB;NECuNVMxPCEQvF2= MUjTRW5ITVJ?
BxPC-3 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;lR|BFUUN3ME20NE42Pjh4IN88US=> M{\ybHNCVkeHUh?=
HSC-2 NIHKbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXKOoh[UUN3ME20NE46OTF|IN88US=> M{\HNXNCVkeHUh?=
UMC-11 M3nTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG0ZpVkUUN3ME20NU4zPjNizszN M2XWfnNCVkeHUh?=
HCC1937 NFW2R25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTONmlKSzVyPUSyMlc5PDNizszN NEizU25USU6JRWK=
Calu-6 NXPhSoZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zpdWlEPTB;NEOuNlM5OiEQvF2= M3G3ZnNCVkeHUh?=
NCI-H1573 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzoTWM2OD12Mz6zOFc4KM7:TR?= MUDTRW5ITVJ?
SK-N-AS NEjmTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR|Lk[wNVkh|ryP MUfTRW5ITVJ?
PSN1 M4rqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi2TWM2OD12NT6yOVQ5KM7:TR?= MUXTRW5ITVJ?
TE-11 M2PKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj5flZ4UUN3ME20OU41QDR{IN88US=> MlraV2FPT0WU
NCI-H1155 MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTR3Lki5Olch|ryP MnqxV2FPT0WU
KM12 NXnwRnRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;pSINKSzVyPUS1MlkxPzZizszN MkPpV2FPT0WU
RO82-W-1 NHu1VmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zlbmlEPTB;NE[uPVgzOiEQvF2= NWrOXIRxW0GQR1XS
SW1573 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkixTWM2OD12Nz6zO|M3KM7:TR?= NYHPWos1W0GQR1XS
CAKI-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTR6LkK4OFUh|ryP Mnr1V2FPT0WU
U-118-MG NWXNenRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfaTJJKSzVyPUS4MlM4ODJizszN NFyweXJUSU6JRWK=
KYSE-520 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH0TWM2OD12OD60NFE3KM7:TR?= NFrNVo9USU6JRWK=
HT55 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLnUpJ5UUN3ME20PU4yPDd2IN88US=> M4jzXnNCVkeHUh?=
ChaGo-K-1 M4\W[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL3[FU1UUN3ME20PU41Pzl|IN88US=> MUfTRW5ITVJ?
IA-LM NVfoOXpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLmTWM2OD13ND62N|IzKM7:TR?= M2O1O3NCVkeHUh?=
UACC-62 M1zNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTV3LkGwOFYh|ryP MleyV2FPT0WU
MKN7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOwSVlyUUN3ME21Ok4xOjh3IN88US=> MmXMV2FPT0WU
HPAF-II NH;aellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PlR2lEPTB;NU[uOFA4OyEQvF2= MlXPV2FPT0WU
NTERA-S-cl-D1 NHXOT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTV5Lke3PEDPxE1? NWDBTnpxW0GQR1XS
FTC-133 M{jj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qyXWlEPTB;NUiuNFk3QSEQvF2= NF;KOYhUSU6JRWK=
MHH-ES-1 M2m2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTQTWM2OD13OD60PFE1KM7:TR?= NYTNUVlJW0GQR1XS
JVM-2 NFfje2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jY[GlEPTB;NUiuPVUxPiEQvF2= NILkfWVUSU6JRWK=
TCCSUP NV\5[oFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjNTWM2OD13OT61Nlc6KM7:TR?= MWHTRW5ITVJ?
COLO-824 NUHqeppKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTZyLkC3NVkh|ryP NGn0bGpUSU6JRWK=
647-V MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfCTWM2OD14MD6xN|Q4KM7:TR?= M4TkTHNCVkeHUh?=
HD-MY-Z M2L3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXjTJR6UUN3ME22NE42Ojl2IN88US=> NVLzVZgzW0GQR1XS
LS-411N MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHhTWM2OD14MT6zPVA{KM7:TR?= M3ThWnNCVkeHUh?=
NCI-H596 M3PWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS4[G9UUUN3ME22Nk44PDl4IN88US=> NY\YOHVPW0GQR1XS
C-33-A M4XkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTZ2LkC5OVch|ryP M1nwTHNCVkeHUh?=
BHY MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzDd2x7UUN3ME22OE4yOjR3IN88US=> M4HNd3NCVkeHUh?=
KGN MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37RUmlEPTB;NkSuOVUyPCEQvF2= MXPTRW5ITVJ?
NCI-H1092 M17Ecmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TGVGlEPTB;NkWuNFA6PSEQvF2= MX;TRW5ITVJ?
MZ1-PC Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZ3LkW2OFkh|ryP MXzTRW5ITVJ?
LB831-BLC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXse21KSzVyPU[1Mlg1QDFizszN NYTifXV6W0GQR1XS
SW620 M17yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\PeGRKSzVyPU[2MlIxOzlizszN NHL1WGlUSU6JRWK=
HuO-3N1 MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF75[ZZKSzVyPU[4MlMzOzhizszN NWGzTWpoW0GQR1XS
SK-HEP-1 M33uVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ryPWlEPTB;NkmuPVQ5PiEQvF2= MlPSV2FPT0WU
LCLC-103H MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHVc3ZsUUN3ME23NE43PzB3IN88US=> MW\TRW5ITVJ?
KYSE-70 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTdyLke4N|Uh|ryP M4jKTHNCVkeHUh?=
Mewo MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli1TWM2OD15MT61NFUh|ryP MnfzV2FPT0WU
COLO-668 NW\zZWxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTdzLki0OVEh|ryP MnryV2FPT0WU
NCI-H522 NH36fHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTd{LkO0NVMh|ryP MoHvV2FPT0WU
NCI-H1437 NETZdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TudWlEPTB;N{SuOFA1QCEQvF2= NGS2W4VUSU6JRWK=
U-266 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTd3LkS1NVYh|ryP NGHqdoNUSU6JRWK=
MC116 M1ziemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO5O4loUUN3ME23OU42PzB6IN88US=> MVvTRW5ITVJ?
PANC-10-05 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPpe3NKSzVyPUe3MlQzPDNizszN NH;2WWVUSU6JRWK=
KYSE-180 M4fINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO1[YlIUUN3ME23O{42PDV2IN88US=> MXPTRW5ITVJ?
JAR NWTDb4NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Tz[2lEPTB;N{muNFU1PiEQvF2= NH\jT3VUSU6JRWK=
CAL-62 NWnn[nNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rk[GlEPTB;OECuNFk2KM7:TR?= NI\QRW9USU6JRWK=
A3-KAW MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\vUVBKSzVyPUiwMlIyPTRizszN NV3abpR[W0GQR1XS
PANC-08-13 M{\FS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXoTWM2OD16MT6xO|Y5KM7:TR?= MmH5V2FPT0WU
HSC-3 NWDrOJZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PINGlEPTB;OEOuN|A4OSEQvF2= MUjTRW5ITVJ?
HTC-C3 M2X6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TKe2lEPTB;OEOuOFcxOiEQvF2= Mmf2V2FPT0WU
KY821 NV\ifndjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTh2LkC4PVIh|ryP MXTTRW5ITVJ?
DoTc2-4510 M1jnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\ZbGFFUUN3ME24OE4zOTh3IN88US=> MV7TRW5ITVJ?
NCI-H1581 NE\1dnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDrS2RKSzVyPUi1MlQ3PDFizszN Mnf1V2FPT0WU
KARPAS-299 NUm3c|BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXjeItKSzVyPUi2MlE6PzdizszN MVXTRW5ITVJ?
IST-MEL1 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXnTWM2OD16Nj64PFczKM7:TR?= Mn75V2FPT0WU
KP-N-YS NHjY[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTh7LkmwNlgh|ryP NFTLc|dUSU6JRWK=
KYSE-410 NY\JZ2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTlzLkSwOFIh|ryP NEX2RmdUSU6JRWK=
TE-10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPaTWM2OD17MT61OlEyKM7:TR?= Mlz4V2FPT0WU
SK-MEL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHYXI1YUUN3ME25Nk46OTB4IN88US=> NInkd5BUSU6JRWK=
COLO-792 NV7KNIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDyTWM2OD17NT6yOVY1KM7:TR?= NVzFVm9uW0GQR1XS
SCH MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLhZ4t6UUN3ME25Ok4{QDd5IN88US=> MUHTRW5ITVJ?
NCI-H1792 NITmdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\IXXV7UUN3ME25Ok45QTl{IN88US=> NWX6PI41W0GQR1XS
NCI-H2029 NYXHdmZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvEOYI4UUN3ME25Ok46PTZ4IN88US=> MmS5V2FPT0WU
SW684 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPxTWM2OD17OD62OlU1KM7:TR?= NXvyOnFzW0GQR1XS
NCI-H209 NX;0[pRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PRT2lEPTB;MUCwMlEzOSEQvF2= MnPpV2FPT0WU
HLE NHjubYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XkN2lEPTB;MUC1MlI5OiEQvF2= MoXKV2FPT0WU
GOTO M{n3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFyNz63O|ch|ryP NVTE[XBTW0GQR1XS
NCI-H1793 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFyOT6yPEDPxE1? NIq1OlFUSU6JRWK=
D-392MG M4flXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFzNz6zPVgh|ryP MYTTRW5ITVJ?
SW1990 M{\jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n1TmlEPTB;MUKwMlk2OSEQvF2= MofJV2FPT0WU
ML-2 NGjyVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O5WmlEPTB;MUKxMlY4PiEQvF2= MkjaV2FPT0WU
NCI-H2452 NXTnPHlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF2yNW1KSzVyPUGyNk4zOSEQvF2= M2P5SHNCVkeHUh?=
SK-MEL-30 NYnrNGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjHTWM2OD1zMkOuNlQ1KM7:TR?= NYH6UW0zW0GQR1XS
SN12C M4HCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\ZfnNKSzVyPUGyOE4yPzZizszN NFfmcVRUSU6JRWK=
NCI-H1770 M4rNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF{NT61NVQh|ryP NGT2fpFUSU6JRWK=
SF268 NHH2S|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTUTWM2OD1zMk[uNVU5KM7:TR?= M2P3ZnNCVkeHUh?=
BALL-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF{Nj6yN{DPxE1? Mn[xV2FPT0WU
COLO-679 M3rKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHmcG1EUUN3ME2xNlYvPzV|IN88US=> NHjzOlNUSU6JRWK=
A2780 NUHRVJkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTvVY1KSzVyPUGyPE46QDhizszN NIrDPYVUSU6JRWK=
NCI-H1651 NYf4XVZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvneIhKSzVyPUGzNU4zPDNizszN NXLZRnV3W0GQR1XS
NCI-H2087 NX;FS5R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjlN2FKSzVyPUGzNU41QDNizszN NUT1V4M5W0GQR1XS
U-87-MG M1KyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PTW2lEPTB;MUOzMlYxPCEQvF2= MkPiV2FPT0WU
LB2518-MEL NWnTdot[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfEWVZbUUN3ME2xN|UvQTl|IN88US=> M4PodXNCVkeHUh?=
HCT-116 NX\UcmlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TsWmlEPTB;MUO3MlIyPyEQvF2= NXfENZBwW0GQR1XS
Ca9-22 NVLOd25wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD1zM{muPFM{KM7:TR?= NYfRNpMzW0GQR1XS
COR-L88 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\wd|BFUUN3ME2xOFIvOTRizszN NELrTYVUSU6JRWK=
CP50-MEL-B M1i4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF2ND61NFEh|ryP NUKyd4l4W0GQR1XS
OVCAR-8 NFvyZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnQ[oRIUUN3ME2xOFUvPjN4IN88US=> MlfIV2FPT0WU
SK-MEL-3 M3vXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XEdGlEPTB;MUS3Mlg4QCEQvF2= Ml\NV2FPT0WU
GT3TKB MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF2OT65Nlgh|ryP MUDTRW5ITVJ?
KYSE-450 NWjxcYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPzOmVKSzVyPUG1NU42OzlizszN NWK3e|c2W0GQR1XS
CAPAN-1 NI\6eYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF3Mz6wOlQh|ryP MV\TRW5ITVJ?
BEN NEDvSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF3Mz65Nlgh|ryP MX;TRW5ITVJ?
NCI-H1304 Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\hTWM2OD1zNUSuOlk1KM7:TR?= NVva[o04W0GQR1XS
KU812 M1j5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF3OD62O|Qh|ryP NEf0V3VUSU6JRWK=
Capan-2 M1vxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnQPHJKSzVyPUG2NE42PTNizszN NGj5ZWdUSU6JRWK=
A673 NFy3dVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v4VmlEPTB;MU[xMlcxPSEQvF2= M4DM[3NCVkeHUh?=
SAS NGfzPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF4Mj62O|gh|ryP Ml73V2FPT0WU
NY NVrLbpJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHtTWM2OD1zNkWuN|E1KM7:TR?= NGHPbJJUSU6JRWK=
HCE-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF4Nj64OFUh|ryP NXjPW4J3W0GQR1XS
MDA-MB-231 M2W0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uy[GlEPTB;MUe3MlUxOyEQvF2= MmW1V2FPT0WU
no-10 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3QbpJkUUN3ME2xO|gvOTN2IN88US=> Mn3MV2FPT0WU
MZ7-mel NHHCb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TXSmlEPTB;MUe4MlQ3PyEQvF2= M{mwR3NCVkeHUh?=
NCI-H82 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP4foNKSzVyPUG4NE4yPjVizszN NHPTb4pUSU6JRWK=
CAL-72 M{\XWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDQb3FWUUN3ME2xPFUvODV2IN88US=> M{jne3NCVkeHUh?=
NCI-SNU-5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF6Nj64OEDPxE1? M2X2cXNCVkeHUh?=
OVCAR-4 NHH3Z2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\kVmlEPTB;MUi4MlM{OyEQvF2= MX;TRW5ITVJ?
SCC-9 M3HmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF7MTFOwG0> Mnr1V2FPT0WU
KYSE-150 M{fBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLOW2hKSzVyPUG5NU45QDhizszN NYnQd2dkW0GQR1XS
HT-29 M4rzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJyMT6yNVIh|ryP NET0[2FUSU6JRWK=
COLO-678 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ziR2lEPTB;MkCxMlQ2KM7:TR?= M4rQN3NCVkeHUh?=
NCI-H650 NYXITY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjsdGhKSzVyPUKwNk4yODNizszN MYnTRW5ITVJ?
HuCCT1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PPWmlEPTB;MkC0MlIxQCEQvF2= MYHTRW5ITVJ?
SW1116 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7NTWM2OD1{MEeuNFc4KM7:TR?= Mn3ZV2FPT0WU
DBTRG-05MG NIHKbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LaWmlEPTB;MkC3MlkxQSEQvF2= NUDpZlY3W0GQR1XS
SW982 NX3VTFAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X3OmlEPTB;MkC3Mlk1QCEQvF2= MXXTRW5ITVJ?
RCM-1 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fhZmlEPTB;MkG0Mlc3OiEQvF2= NFvWUJNUSU6JRWK=
COLO-320-HSR M3\IOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zlXWlEPTB;MkG2MlEzPSEQvF2= MX;TRW5ITVJ?
KNS-42 M1LKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXxTWM2OD1{MU[uOVc1KM7:TR?= NH\vN4JUSU6JRWK=
C2BBe1 NWTxe4FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJ|MT65NFUh|ryP MkX0V2FPT0WU
CCRF-CEM MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XRdGlEPTB;MkSzMlc6PSEQvF2= MVvTRW5ITVJ?
SH-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nzZmlEPTB;MkS2MlA6KM7:TR?= MXjTRW5ITVJ?
LS-1034 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnhV|VKSzVyPUK0Ok4zPjZizszN NXTVToxNW0GQR1XS
NCI-H2347 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q4V2lEPTB;MkS3MlcyOyEQvF2= M{XkOHNCVkeHUh?=
RPMI-8866 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n6R2lEPTB;MkS5MlI4KM7:TR?= MnzWV2FPT0WU
GAK NHfqWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHWOI1YUUN3ME2yOVMvODB{IN88US=> NFzs[pdUSU6JRWK=
NB6 NXm1d2ttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jZNWlEPTB;MkewMlEh|ryP MnjJV2FPT0WU
COLO-680N NHu4ZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXTZnFYUUN3ME2yO|IvPTJ5IN88US=> NVTsZ2VpW0GQR1XS
RERF-LC-MS M3LCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjOfphKSzVyPUK3Ok4xODdizszN M3TpPXNCVkeHUh?=
TGBC11TKB MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn4RWFFUUN3ME2yO|gvOTd6IN88US=> MWDTRW5ITVJ?
C8166 NF3DTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKwVnhtUUN3ME2yO|gvPTB4IN88US=> MVrTRW5ITVJ?
HDLM-2 M37tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTucppFUUN3ME2yPVQvPDB7IN88US=> M1fQOnNCVkeHUh?=
IGR-1 M1vXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W0WWlEPTB;Mkm1MlY2QSEQvF2= M1n2[3NCVkeHUh?=
FADU NHLEd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyyUWdKSzVyPUK5O{42OSEQvF2= Ml;HV2FPT0WU
L-428 NFHte4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfYTWM2OD1{OUeuOlE3KM7:TR?= M1r4N3NCVkeHUh?=
LU-65 NYLjRXhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\mWmlEPTB;M{C0MlMzKM7:TR?= NF7ZZYJUSU6JRWK=
HEL M4r6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfrTWM2OD1|MEmuPVg{KM7:TR?= NHGySZVUSU6JRWK=
NCI-H810 NHXWN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\wTWM2OD1|MUCuOVch|ryP MYnTRW5ITVJ?
C3A NEjqVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK1VWhHUUN3ME2zNVEvQDB{IN88US=> MYTTRW5ITVJ?
NCI-H630 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\DTWM2OD1|M{KuNlk1KM7:TR?= MX7TRW5ITVJ?
KP-N-YN NH3od4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HGZ2lEPTB;M{SxMlEzOyEQvF2= M2jyeHNCVkeHUh?=
MOLT-13 M{TWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTZdZFKSzVyPUO0Nk4{OjZizszN NXTuW2F[W0GQR1XS
NCI-H1993 M1rUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTN2Mj6zOlUh|ryP NX7yZYR4W0GQR1XS
BE-13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDEbnpKSzVyPUO0OE4yPjdizszN MVzTRW5ITVJ?
IST-SL1 NEHqS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnqTWM2OD1|NEeuOFAyKM7:TR?= NUP1TndnW0GQR1XS
TE-9 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN4Mz61PFkh|ryP Mnq2V2FPT0WU
LU-135 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHhTWM2OD1|NkeuNFM2KM7:TR?= MmXJV2FPT0WU
T84 NXzFSWp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTN5ND63NVIh|ryP MnvDV2FPT0WU
K-562 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjFZlhKSzVyPUO4N{4{PiEQvF2= MYLTRW5ITVJ?
SBC-5 NEKyblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN6Nj65PFUh|ryP MmTPV2FPT0WU
NB17 M4\1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GxRmlEPTB;M{myMlU6PiEQvF2= MV3TRW5ITVJ?
NCI-H2052 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULM[YFqUUN3ME2zPVgvPDd{IN88US=> NYr6PFRYW0GQR1XS
HCC38 NIXo[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTsfIJjUUN3ME20NFEvPTl|IN88US=> MmXIV2FPT0WU
NCI-H69 M3\sZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTR2MT6wPFMh|ryP MoPNV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 MK-2206和这些细胞毒素药剂联用作用于NCI-H292移植瘤,MK-2206显示出非常有效的抗癌活性。卵巢癌A2780移植瘤中,按动物体重,每千克处理240mg MK-2206,则可抑制70%以上的Akt1/2在苏氨酸308位点和丝氨酸473位点的磷酸化,导致肿瘤生长抑制率达到60%。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[3]

+ 展开

Akt激酶实验:

通过得到的GSK 生物素肽段基质测定Akt激酶。使用含镧系金属螯合物偶联单抗的均相时间分辨荧光(HTRF)测定肽段磷酸化程度,这种单抗专门作用于与链霉亲和素——藻蓝素(SA-APC)载体相结合的磷酸化作用,SA-APC载体可以结合到肽段的部分生物素上。当镧系金属螯合物与藻蓝素相接触时,无辐射的能量从镧系金属螯合物传递给藻蓝素,然后藻蓝素发射波值为655纳米的光线。工作液:100X 蛋白酶抑制剂混合物(PIC):1mg/ml苯甲脒,0.5 mg/ml 抑肽素, 0.5 mg/ml亮抑肽酶, 0.5 mg/ml 抑肽酶。10X实验 buffer: 500 mM HEPES(pH 为7.5), 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-甘油磷酸。抑制 buffer:50 mM HEPES(pH为7.3), 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM 标记的单抗, 0.0067mg/ml SA-APC。ATP/MgCl2工作液: 1X 实验buffer, 1 mM DTT, 1X PIC, 5% 甘油, 激活的Akt。肽段工作液:1X实验buffer, 1 mM DTT, 1X PIC, 5% 甘油 2 TM GSK生物素肽段。工作液加到合适的孔中,然后加入总负荷为16的 ATP/MgCl2,反应开始。含MK-2206的实验组和对照组加入总负荷为10的肽段工作液。然后加入总负荷为13的酶液,混匀。反应进行50分钟,然后加入总负荷为60的均相时间分辨荧光抑制buffer停止反应。阻断的反应在室温下温育30分钟以上,然后使用仪器读数。
细胞实验:

[2]

+ 展开
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6,和NCI-H460细胞
  • Concentrations: 0, 0.3, 1,和3 μM
  • Incubation Time: 72或96小时
  • Method:

    MK-2206溶解在DMSO中,在实验使用前用培养基稀释。细胞按2~3×103密度接种在96孔板上,温育24小时。MK-2206 (分为0, 0.3, 1,和3 μmol四组)处理细胞,72或者96小时后,测定细胞增殖情况。


    (Only for Reference)
动物实验:

[2]

+ 展开
  • Animal Models: 携带SK-OV-3, NCI-H292, HCC70, PC-3,和NCI-H460模型的雄性CD1裸鼠
  • Formulation: 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
15% Captisol
17 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 480.39
化学式

C25H21N5O.2HCl

CAS号 1032350-13-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01263145 Completed Adult Solid Neoplasm|Recurrent Breast Carcinoma|Stage IV Breast Cancer National Cancer Institute (NCI) January 5 2011 Phase 1
NCT01239342 Active not recruiting Metastatic Renal Cell Cancer|Recurrent Renal Cell Carcinoma|Stage IV Renal Cell Cancer National Cancer Institute (NCI)|M.D. Anderson Cancer Center January 27 2011 Phase 2
NCT01306045 Recruiting Carcinoma Non-Small-Cell Lung|Carcinoma Small Cell Lung|Carcinoma Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 26 2011 Phase 2
NCT01604772 Completed Recurrent Oral Cavity Adenoid Cystic Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Adenoid Cystic Carcinoma|Stage IVA Major Salivary Gland Cancer AJCC v7|Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7|Stage IVB Major Salivary Gland Cancer AJCC v7|Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7|Stage IVC Major Salivary Gland Cancer AJCC v7|Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 National Cancer Institute (NCI) July 23 2012 Phase 2
NCT01480154 Active not recruiting Adult Solid Neoplasm|Hormone-Resistant Prostate Carcinoma|Recurrent Melanoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7 National Cancer Institute (NCI) November 23 2011 Phase 1
NCT01251861 Active not recruiting Recurrent Prostate Carcinoma|Stage I Prostate Cancer AJCC v7|Stage IIA Prostate Cancer AJCC v7|Stage IIB Prostate Cancer AJCC v7|Stage III Prostate Cancer AJCC v7 National Cancer Institute (NCI) December 23 2010 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • 回答:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • 问题 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • 回答:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

相关Akt产品

Tags: 购买MK-2206 2HCl | MK-2206 2HCl供应商 | 采购MK-2206 2HCl | MK-2206 2HCl价格 | MK-2206 2HCl生产 | 订购MK-2206 2HCl | MK-2206 2HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID